Kelly Stone
Psychiatric/Mental Health · Loves Park, ILNPI 1104464767
Payments from drug & device makers
Across 1,030 payments — averaging $22.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$2K
- Teva Pharmaceuticals USA, Inc.$2K
- Vanda Pharmaceuticals Inc.$2K
- Harmony Biosciences LLC$2K
- plus $12K from 21 others
What the payments were for
- Food & beverage$22,57198%
- Education$4402%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 82 | $2,195 |
| Otsuka America Pharmaceutical, Inc. | 84 | $2,079 |
| AbbVie | 109 | $1,882 |
| Teva Pharmaceuticals USA, Inc. | 68 | $1,776 |
| Vanda Pharmaceuticals Inc. | 70 | $1,678 |
| Harmony Biosciences LLC | 76 | $1,612 |
| Neurocrine Biosciences, Inc. | 69 | $1,581 |
| Supernus Pharmaceuticals, Inc. | 66 | $1,481 |
| Axsome Therapeutics, Inc. | 60 | $1,477 |
| Alkermes, Inc. | 52 | $1,281 |
| Johnson & Johnson | 44 | $1,261 |
| Lundbeck LLC | 65 | $1,161 |
| Ironshore Pharmaceuticals Inc. | 27 | $707 |
| E.r. Squibb & Sons, L.L.C. | 30 | $650 |
| Takeda Pharmaceuticals U.S.A., Inc. | 44 | $570 |
| Collegium Pharmaceutical, Inc. | 17 | $413 |
| Corium, LLC | 23 | $388 |
| Idorsia Pharmaceuticals US Inc | 10 | $189 |
| Jazz Pharmaceuticals Inc. | 4 | $159 |
| Indivior Inc. | 12 | $143 |
| OWP Pharmaceuticals, Inc. | 4 | $86 |
| Almatica Pharma LLC | 4 | $77 |
| Livanova USA, Inc. | 2 | $58 |
| Sunovion Pharmaceuticals Inc. | 4 | $36 |
| Merck | 2 | $32 |
| Eisai Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$1,078
- LYBALVI$625
- CAPLYTA$577
- INGREZZA$363
- SPRAVATO$358
- QELBREE$357
- Austedo XR$340
- COBENFY$257
- REXULTI$241
- JORNAY PM$238
- Auvelity$235
- ABILIFY MAINTENA$232
- INVEGA SUSTENNA$133
- ARISTADA INITIO$125
- Fanapt$125
- ABILIFY ASIMTUFII$122
How this compares
$23,011 in reported general payments places this provider in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 20 | $160,246 |
| VraylarCariprazine Hcl | 35 | $50,048 |
| RexultiBrexpiprazole | 16 | $25,183 |
| SaphrisAsenapine Maleate | 12 | $21,861 |
| QuviviqDaridorexant Hcl | 41 | $20,676 |
| TrintellixVortioxetine Hydrobromide | 17 | $9,115 |
| Lurasidone Hcl | 22 | $4,866 |
| ConcertaMethylphenidate Hcl | 11 | $4,355 |
| Aripiprazole | 40 | $1,675 |
| Duloxetine Hcl | 81 | $1,619 |
| Quetiapine Fumarate | 68 | $1,601 |
| Olanzapine | 36 | $1,450 |
| Bupropion XlBupropion Hcl | 54 | $1,343 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $949 |
| Fluoxetine Hcl | 82 | $802 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,581 | $160,24620 claims |
| AbbVieVraylar, Saphris | $1,882 | $71,90847 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,079 | $25,18316 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $189 | $20,67641 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $570 | $9,11517 claims |
| Johnson & JohnsonConcerta | $1,261 | $4,35511 claims |
| Almatica Pharma LLCSertraline Hcl | $77 | $34956 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 922 psychiatric/mental health providers in Illinois.
Other psychiatric/mental health in Loves Park
- Kayla CareyLoves Park$24K
- Erin PetrusicChicago$517K
- Maurice BrownleeChicago$162K
- Melissa VitaleChicago$151K
- Alan AmbergChicago$119K
- Jaime MendozaMaryville$111K
- Jennifer TheryMaryville$83K
- Carole Weddington HuntGranite City$67K
- Jessica WhelanBloomington$55K
- Lynn LochnerKankakee$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.